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We present the functional and structural effects of seven novel (p.Leu12Met, p.Arg16Cys, p.Ser101Asn, p.Ser202Gly, p.Pro267Leu,
p.Gln389 Ala391del, and p.Thr450Met) and two previously reported but not studied (p.Ser113Phe and p.Thr450Pro) CYP21A2
mutations. Functional analyses were complemented with in silico prediction of mutation pathogenicity based on the recently
crystallized human CYP21A2 structure. Mutated proteins were transiently expressed in COS-1 cells and enzyme activities towards
17-hydroxyprogesterone and progesterone were determined. Residual enzyme activities between 43% and 97% were obtained
for p.Arg16Cys, p.Ser101Asn, p.Ser202Gly, p.Pro267Leu, and p.Thr450Met, similar to the activities of the well-known nonclassic
mutations p.Pro453Ser and p.Pro482Ser, whereas the p.Leu12Met variant showed an activity of 100%. Conversely, the novel
p.Ser113Phe, p.Gln389 Ala391del, and p.Thr450Promutations drastically reduced the enzyme function below 4%.The𝐾
𝑚
values for
all novel variants were in the same order of magnitude as for the wild-type protein except for p.The450Met.The maximum velocity
was decreased for all mutants except for p.Leu12Met. We conclude that p.Leu12Met is a normal variant; the mutations p.Arg16Cys,
p.Ser101Asn, p.Ser202Gly, p.Pro267Leu, and p.Thr450Met could be associated with very mild nonclassic CAH, and the mutations
p.Ser113Phe, p.Gln389 Ala391del, and p.Thr450Pro are associated with classic CAH. The obtained residual activities indicated a
good genotype-phenotype correlation.
1. Introduction
Congenital adrenal hyperplasia (CAH) is caused by defects
in one of the steroidogenic enzymes involved in the adrenal
steroid biosynthesis from cholesterol to cortisol. The most
common cause ofCAH is 21-hydroxylase deficiency (21OHD)
where patients with the classic form present with or without
salt loss (salt wasting or simple virilizing forms, resp.) during
the neonatal period and affected females are born with
virilized external genitalia. In the nonclassic form, signs
of androgen excess such as acne, hirsutism, and menstrual
irregularities can be observed as late as during adolescence
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and adulthood. Children present with precocious pubarche,
accelerated growth velocity, and advanced skeletal matu-
ration [1]. The worldwide incidence of classic 21OHD is
1 : 10.000 to 1 : 15.000 live births, while nonclassic 21OHD
is much more prevalent occurring in 1 : 500 live births in
Caucasian populations [2–5].
The CYP21A2 gene coding for the 21-hydroxylase enzyme
is formed by 10 exons and 9 introns located on the short
arm of chromosome 6 [6, 7]. CYP21A2 is arranged in tandem
with a nonfunctional pseudogene (CYP21A1P) that shares
98% sequence identity with the active gene [8, 9]. There
are common pseudogene-derived mutations identified in
CYP21A2 that are found in more than 95% of all CAH alleles.
In general, the less severe mutation present in the genotype
determines the phenotype, establishing a good genotype-
phenotype correlation [10]. Furthermore, in vitro studies
indicate that mutated CYP21A2 residual enzyme activities
present a good correlation with in vivo disease severity [11–
13]. Therefore, in vitro analysis for novel or rare mutations
is proposed as a complement for disease classification, espe-
cially where large groups of patients are not available for
clinical investigation, thereby improving genetic counselling
and clinical management [14–17].
In this report, we describe a detailed evaluation of the
functional role of seven novel (p.Leu12Met, p.Arg16Cys,
p.Ser101Asn, p.Ser202Gly, p.Pro267Leu, p.Gln389 Ala391del,
and p.Thr450Met) and two previously reported but not func-
tionally studied (p.Ser113Phe and p.Thr450Pro) CYP21A2
mutations [18, 19]. The aim of the study was to inves-
tigate the pathogenicity of novel/rare mutations using in
vitro assays and to establish a correlation between their in
vitro effect and a possible CAH phenotype. In order to
reach a reliable phenotype prediction, we also expressed
four mutations (p.Ile172Asn, p.Val281Leu, p.Pro453Ser, and
p.Pro482Ser) known to cause CAH of different severity, as
well as a CYP21A2 normal variant (p.Ala15Thr). Further-
more, we complemented the functional analyses with in silico
predictions of mutation pathogenicity and the effects on
protein structure using the model of the recently crystallized
human CYP21A2 structure [20].
2. Material and Methods
2.1. Genotyping. CYP21A2 genotypingwas performed at Uni-
versidade Estadual de Campinas, Brazil, and at Karolinska
University Hospital, Sweden. The study was approved by the
Ethics Committee of Universidade Estadual de Campinas
and the Regional ethics committee of Karolinska Institutet.
Genomic DNA was obtained from peripheral blood by
phenol/chloroformextraction.TheCYP21A2 genewas specif-
ically amplified in two or four fragments, depending on the
presence or absence of the variant C at the intron 2 c.290-
13A/C>G position [21]. Sequencing of the amplified products
has been performed using the BigDye Terminator v3.1 Cycle
Sequencing kit (Applied Biosystems, USA) according to the
manufacturer’s instructions. Fragments were separated on a
Genetic Analyzer from Applied Biosystems (ABI PRISM
3100 Genetic Analyzer/Life Technologies, USA). Electro-
pherograms were analyzed against the reference sequence
NM 000500.6. Segregation analysis was performed in all
subjects by sequencing parental samples, except for subject 3.
2.2. Subjects. Clinical and molecular data of the subjects are
summarized in Table 1.
Subject number 1, a girl, presented with premature pub-
arche and accelerated growth velocity at the age of 4 years.
She had clitoral enlargementwithout labioscrotal fusion since
birth (Prader I). Due to advanced bone age (8.7 y at 6.4 y
chronological age) she was subjected to 250𝜇g Synacthen
stimulation test that exhibited an elevation in the 17OHP
basal level from 13 nM to >154 nM at 60min. The child was
diagnosed with NC CAH and CYP21A2 genotyping revealed
a complex genotype with a novel mutation p.Leu12Met
together with p.Gln318∗ on the maternal allele and the NC
mutation p.Val281Leu on the paternal allele.
Subject number 2 came to medical attention when her
daughter was diagnosed with CAH and the family was
genotyped for 21OHD. She did not complain of any symptoms
of androgen excess and stimulation with Synacthen raised
the 17OHP basal level just above the cut-off at 60min (6
to 31 nM). CYP21A2 genotyping revealed a novel mutation,
p.Ser101Asn, in compound heterozygosity with p.Val281Leu.
Therefore, very mild NC CAH was suspected but was not
clinically confirmed in this case.
Subject number 3, a female, presented with menstrual
irregularities, hirsutism and a clinical suspicion of NC CAH
at the age of 26 years.CYP21A2 genotyping revealed the com-
mon p.Val281Leu mutation and the novel p.Ser113Phe amino
acid change. Although segregation analyses or biochemical
investigational data were not available, we assumed that the
genotype could be responsible for her clinical presentation
and NC CAH.
Subject number 4, a girl, was born appropriate for
gestational age at gestational week (GW) 36 and detected
via the neonatal screening program. The 17OHP screening
level (106 nM) was slightly above the cut-off level (100 nM).
The second tier remained elevated (66 nM, cut-off 60 nM,
GW37+2). At birth she had no signs of virilization or salt loss.
At 6 months of age, a 250 𝜇g Synacthen stimulation test was
normal. Due to her borderline hormonal screening values
CYP21A2 genotyping was performed. The novel p.Ser202Gly
mutation was identified in trans with p.Gln318∗. Very mild
NC CAH could at this stage not be ruled out.
Heterozygosity for the p.Ser202Gly variant was also iden-
tified in subjects number 5 and number 6 at the ages of 1
month and 9 years, respectively. Both children were initially
seen at a primary reference center and investigated for sus-
pected signs of androgen excess. However, the analyses of
17OHP, genotyping, and clinical examination could not con-
firm the diagnosis of CAH.These subjects are thus heterozy-
gous carriers for the novel p.Ser202Gly mutation.
Subject number 7, a girl, was virilized at birth (Prader IV)
and presented with a salt-losing crisis at day 7. SW CAH was
confirmed due to elevated levels of 17OHP and subsequent
genotyping identified that she was compound heterozygous
for the novel in-frame deletion p.Gln389 Ala319del inherited
from her father and a 30-kb deletion inherited from her
mother.
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The detailed clinical presentation of subject number 8 has
been previously described [19]. The girl was born virilized
(Prader V) and presented with an adrenal crisis at day 33. She
was found to be homozygous for the p.Thr450Pro mutation.
Subjects numbers 9, 10, and 11 presented with different
signs of androgen excess and clinical suspicion of CAH;
for summary see Table 1. However, 17OHP levels remained
within the normal range even after Synacthen stimulation.
Genotyping revealed that these subjects were heterozygous
carriers for three novel mutations, p.Arg16Cys, p.Pro267Leu,
and p.Thr450Met, respectively. Since the functional con-
sequences for these novel amino acid substitutions were
unknown, they were included in the present investigation.
2.3. Functional Studies. The general description for the con-
struction of vectors used in the COS-1 expression studies of
mutated CYP21A2 has been previously described [11, 22].
Expression of wild-type and mutant CYP21A2 enzymes
and assays of 21OH activity were performed as previously
described [23, 24]. Enzyme activities were expressed as a
percentage of conversion, taking the apparent specific activity
of the CYP21A2 wild type as 100%. Assays were performed
after 40min of incubation time.
Apparent kinetic constants were determined 24 h after
transfection. Intact cells were incubated as previously
described [23] together with 0.5, 1.0, 2.0, 3.0, or 6.0𝜇M
of unlabeled 17-hydroxyprogesterone (Sigma-Aldrich, Saint
Louis, USA) as substrate. After incubation at 37∘C for 20min,
steroids were extracted and analyzed as previously described
[23]. Apparent kinetic constants were calculated after lin-
ear regression of the data derived from determinations of
enzymatic activity at each of the five different substrate
concentrations.
2.4. Western Blot. To ascertain similar amount of CYP21A2
expression in transfected cells, Western blotting was per-
formed using rabbit polyclonal antibodies against human
CYP21A2 as primary antibody (Sigma-Aldrich, Saint Louis,
USA) and anti-rabbit IgG (GE Healthcare Life Sciences,
Freiburg, Germany) as the secondary antibody; see Robins
et al. [23] for details.
2.5. Structural Evaluation. The resolved three-dimensional
structure of human CYP21, pdb id: 4y8w [18], was used as
a starting point to evaluate the effect of the novel mutations
on the protein structure. The ICM molecular modelling
software (version 3.8-1, Molsoft LLC, La Jolla, CA) was used
to perform structural calculations of the structures of each
mutation, expanding on the strategy previously described
[25]. First, all missing intrastructural loops were added to the
4y8w structure and the structure was optimized using energy
minimization. A model of each mutation was then generated
by modifying the corresponding amino acid residue, fol-
lowed by multiple steps of energy minimization. The energy
minimization was initially performed with strong backbone
restraints, which were gradually relaxed and finally a global
minimization without backbone restraints was performed.
Each mutation was then evaluated based on energy and
distances to the steroid and heme, as well as using the
ICM built-in function for evaluating stability changes from
mutations by calculating the free energy changes.
The BLAST web interface [26] was used to identify mam-
malian proteins similar to the human CYP21A2 enzyme.The
search was performed on the Nov 2015 release of the Refseq
database and resulted in CYP21 protein sequences from 81
mammals. The sequences with the highest similarity to the
human CYP21A2 protein, one sequence per species, were
retrieved from the database. The retrieved sequences were
aligned using the Linsi approach ofMAFFT [27], and for each
position the sequence identity was calculated, counting a gap
as a mismatch.
3. Results
We have determined the residual activities of seven novel
CYP21A2 mutations (p.Leu12Met, p.Arg16Cys, p.Ser101Asn,
p.Ser202Gly, p.Pro267Leu, p.Gln389 Ala391del, and
p.Thr450Met) and of two previously reported but not func-
tionally studied alterations (p.Ser113Phe and p.Thr450Pro).
Neither of the variants was present in the pseudogene. We
compared the data to the residual activities of fivewell-known
reference mutations (p.Ala15Thr, p.Ile172Asn, p.Val281Leu,
p.Pro453Ser, and p.Pro482Ser) using in vitro functional
assays. The different residual enzyme activities ranged from
normal to completely abolished enzyme function and the
mutations could therefore be defined as being normal poly-
morphisms or being able to cause CAH of various degrees of
severity; Figure 1 and Table 3 illustrate the results. In order
to unravel the mechanism responsible for reduced enzyme
function and to better differentiate between a very mild
mutation and a neutral amino acid change we determined
the apparent kinetic constants for all mutants that exhibited
a residual enzyme activity above 80% compared to the
wild-type protein (Table 2). 𝐾
𝑚
(substrate-binding capacity)
for all variants was in the same order of magnitude as for
the wild-type protein except for the p.Thr450Met mutation.
The maximum velocity (𝑉max) was decreased for all variants,
except for p.Leu12Met and for the reference mutation
p.Arg15Thr, and both are thus considered to be normal
variants (Table 2).
Equal protein expressions of mutant and wild-type pro-
teins have been confirmed by Western blotting (data not
shown).
Table 3 summarizes the biochemical results, the putative
effects on the protein structure for all mutants, and the
final prediction of the phenotype. Structural calculations for
p.Ser101Asn, p.Ser113Phe, Ser202Gly, and p.Pro267Leu are
also illustrated in Figure 2.The p.Pro267Leu mutation has no
effect on protein structure, whereas p.Ser101Asn, p.Ser202Gly,
and p.Thr450Met are predicted to have a minor effect.
Conversely, p.Ser113Phe produces a more severe effect on
protein structure since it interferes with the alfa helices
comprising the active site.The p.Thr450Promutation and the
p.Gln389 Ala391del in-frame deletion are predicted to have
deleterious effects on the CYP21A2 structure.
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Figure 1: Enzymatic activities of CYP21A2 mutant proteins. Activities are expressed as a percentage of wild-type activity, which is arbitrarily
defined as 100%. Conversion values are shown for the two natural substrates (17OHP and progesterone).
Table 2: Apparent kinetic constants using 17-OHP as substrate.
𝑉max
(pmol/mg
protein per
min)
𝐾
𝑚
(𝜇M) 𝑉max/𝐾𝑚
Wild type 519 (93) 12.5 (1.3) 42 (9)
p.Leu12Met 618 (207) 17.7 (5.2) 35 (4)
p.Ala15Thr 671 (145) 16.9 (6.5) 42 (8)
p.Arg16Cys 181 (31) 5.0 (1.1) 37 (3)
p.Ser101Asn 326 (67) 9.7 (2.0) 34 (4)
p.Ser202Gly 244 (47) 8.0 (1.5) 31 (5)
p.Pro267Leu 320 (93) 8.4 (1.9) 38 (7)
p.Thr450Met 43 (5) 1.2 (0.1) 35 (5)
Values are present as the mean (1SD) of at least four experiments.
4. Discussion
Nine novel/rare mutations, identified in individuals investi-
gated and genotyped for CAH, have been expressed in vitro
and enzymatic activities were compared with the functional
activity of the wild-type protein. Five other well-known
reference mutations were included in the assay.The reference
mutations present a gradient of increasing residual activities
that are associated with the CAH phenotype variability. The
p.Ile172Asn mutation is a classic mutation in most cases
leading to SV CAH [28], with a very low residual enzyme
activity towards both 17OHP and progesterone. The muta-
tions p.Val281Leu, p.Pro453Ser, and p.Pro482Ser are three
NC CAHmutations that present different degrees of residual
activity, p.Pro482Ser being the mildest variant [29] and
p.Val281Leu being the most frequent mutation causing NC
CAH with a residual activity of approximately 50% [30]. At
last, p.Ala15Thr is considered to be a neutral amino acid
change [29]. Expressing these well-characterized mutations
at the same time as the novel mutations allowed a better
intercomparison among mutants and provided a genotype-
phenotype prediction.
Two of the analyzed mutations, p.Leu12Met and
p.Arg16Cys, are located in the first hydrophobic domain of
the protein. This region comprises the membrane targeting,
anchoring domain and is important for in vitro stability [31].
It is unsuitable for computational protein structure analysis
and is missing from the published crystal structures [20, 32].
Leu12 is highly conserved among mammalian species (88%).
Arg16 is also well conserved (69%) and the corresponding
amino acid residue in bovine is histidine, indicating conser-
vation of a positively charged, polar residue. Interestingly,
another mutation within this region, p.Ala15Thr, is a normal
variant [29]. The mutation p.Leu12Met was identified in cis
with the p.Gln318∗ mutation and consequently this is a null
allele, whereas the p.Arg16Cys was identified in a heterozy-
gous carrier. Therefore it was impossible to evaluate their
pathogenicity based on the phenotype of the subjects
(Table 1). In vitro functional studies showed that the mutant
p.Leu12Met did not demonstrate a significant difference in
enzymatic activity or in kinetic constants when compared
with the wild-type and p.Ala15Thr proteins. It is therefore
considered to be a normal variant. The p.Arg16Cys mutant
demonstrated a very mild reduction in enzyme activity,
similar to p.Pro482Ser (Table 3) in addition to a clear reduc-
tion in apparent𝑉max (Table 2). Although we did not identify
a compound heterozygous patient to confirm our hypothesis,
this mutation may be associated with a very mild NC CAH
phenotype.
The p.Ser101Asn mutation was identified in an asymp-
tomatic mother of a Brazilian CAH patient (Table 1). She
was compound heterozygous for the p.Val281Leu mutation
that was transmitted to her daughter. Ser101 is conserved
amongmammalian species (74%) and is located between two
residues that are part of the channel for product passage [32].
However, the structural calculations implied only a minor
effect on protein structure caused by the mutation. In fact,
in vitro studies confirmed a very mild effect with a reduction
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Figure 2: Structural changes. Visualization of the structural changes caused by fourmutations; left: wild type; right:mutation; (a) p.Ser101Asn,
(b) p.Ser113Phe, (c) p.Ser202Gly, and (d) p.Pro267Leu.
of activity to 94% and 74% towards 17OHP and progesterone,
respectively.𝑉max value was also reduced as shown in Table 2.
Based on our results we may expect this mutation to result
in very mild NC CAH. However, we could not confirm
our hypothesis because the individual did not present any
obvious symptoms and a neutral amino acid change could not
completely be ruled out.
The mutation p.Ser113Phe may disturb an adjacent 𝛼-
helix based on the structural calculations for the model of
humanCYP21A2. It is located in the vicinity of Ser109, Leu110,
and Trp117, which form part of the proximal substrate-
binding pocket and the heme-binding region [32]. Therefore
this amino acid substitution may interfere with the recogni-
tion and binding of the substrate and, consequently, affect
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enzyme activity.The in silico predictions were in line with the
in vitro studies where a minimal activity of 4% towards both
substrates was obtained (Table 3). Consequently, p.Ser113Phe
can be associated with SV CAH if found in a homo- or
hemizygous state. Although p.Ser113Phe had been previously
reported by Haider et al. [18] as a NC mutation, no patient
description or in vitro studies were presented in the first
report.
The p.Ser202Gly mutation was identified in three inde-
pendent subjects from two different continents. The two
Brazilian carriers were genotyped because CAH was sus-
pected but no othermutations were identified. In the Swedish
subject, however, it was identified in compoundheterozygosis
with the null mutation p.Gln318∗. This girl has been followed
during her first year of life and so far no signs of virilization
have been detected, but a NC CAH phenotype cannot be
ruled out at this young age. Functional studies showed a
reduction in enzyme activity to the level of the NC mutation
p.Pro482Ser and a reduced 𝑉max (Tables 2 and 3). The
structural calculations implied that this mutation causes a
minor effect on protein structure since both serine and
glycine are small amino acid residues and Ser202 is located
in a loop close to the surface of the protein.
The p.Pro267Leu mutation was identified in a girl that
was investigated for premature pubarche at 4 years of age.
CYP21A2 genotyping indicated that she was a heterozygous
carrier for this mutation. Pro267 is weakly conserved among
mammalian species (51%) and is located in a loop between
two 𝛼-helices. The structural calculations did not show any
notable structural changes. Functional studies showed a
minor effect on enzyme activity similar if not milder than for
p.Pro482Ser. Kinetic studies showed a reduction in 𝑉max but
to finally exclude p.Pro267Leu as a neutral variant additional
and symptomatic CAH cases with this mutation need to be
identified (Table 2).
The in-frame deletion of three amino acids (p.Gln389
Ala391del) is the result of the nucleotide deletion c.1165
1173delCAAGGCGCC in exon 9. Based on the phenotype of
the patient who has SW CAH (Table 1) a drastic effect on the
enzyme activity could be predicted.The patient is compound
heterozygous for this mutation inherited from her father and
a 30-kb deletion inherited fromhermother.The three deleted
residues (Glu, Gly, and Ala) are highly conserved among
mammalian species (83%, 94%, and 94%, resp.). Based on
the structural analysis of human CYP21A2, these amino acids
are located inside an 𝛼-helix just before a His that has been
shown to interact with the EXXR structural motif, important
for the tertiary structure of the CYP21A2 enzyme [32]. The
deletion by itself may be deleterious to the structure or func-
tion of the protein. In vitro studies confirm the loss of enzyme
activity. No reduction in protein level was seen by Western
blot analysis (data not shown), although specific stability
studies have not been performed.
Finally, the novel mutation p.Thr450Met has been iden-
tified in a heterozygous carrier in the Brazilian population.
Previously, the p.Thr450Promutationwas identified in an Ira-
nian girl with SW CAH (Table 1). Thr450 is highly conserved
(89%) amongmammalian species and is located inside a short
𝛽 sheet, which is disturbed by the p.Thr450Pro mutation.
The 𝛽 sheet is not central to the protein, but the structural
calculations imply that the mutation affects protein structure
significantly. The p.Thr450Met substitution, however, does
not disturb the 𝛽 sheet to the same extent. We expressed
both mutant proteins in vitro and obtained results that con-
firmed the structural predictions (Table 3). The p.Thr450Pro
mutation had a drastic effect on enzyme function, similar
to the classic reference mutation p.Ile172Asn, whereas the
p.Thr450Met mutant gives a milder reduction in enzyme
activity to the level of other NC mutations (Table 3) but with
a more severe impact on apparent kinetic constants (Table 2).
5. Conclusions
We studied the functional effects of nine novel/rare muta-
tions in the CYP21A2 enzyme. We conclude that p.Leu12Met
is a normal variant and the mutations p.Ser113Phe, p.Gln389
Ala391del, and p.Thr450Pro are associated with classic CAH.
The mutations p.Arg16Cys, p.Ser101Asn, p.Ser202Gly,
p.Pro267Leu, and p.Thr450Met could be associated with
milder forms of nonclassic CAH, although the identification
of additional symptomatic cases will further define the clini-
cal spectrum for these variants. The study showed a good
correlation between genotype and phenotype for mutations
identified in compound heterozygous individuals. Further-
more, the putative effects on protein structure based on
in silico predictions using the recently crystallized human
CYP21A2 structure confirmed the pathogenicity of themuta-
tions and the results were in agreement with the functional
studies.
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